Quanta Pharma Tirzepatide 60mg + Free BW
Quanta Pharma Tirzepatide 60mg + Free BW
In short 产品简述
Quanta Pharma Tirzepatide 60mg is a dual agonist peptide that activates both the GLP-1 and GIP receptors. It enhances insulin secretion and decreases glucagon levels, leading to improved glycemic control and weight loss. Lab verified 99.90% purity.
Specifications 规格参数
About the Product 产品详情
Included Free
+ 3ml Bacteriostatic Water with order
Independently Lab Verified
One new finished product test plus an independent blind screen
Reports
Labs
99%+
Purity
Finished Product Test (Sealed Vial)
New Just Tested
ANALIZA BIAŁEK
Actual Content
Label Claim
Purity
Sample:
Sealed lyophilised vial |
Order:
100015227 |
Method:
HPLC (BioBasic 8 Thermo Scientific) |
Verification Key:
1E75T4NS
Tested 16 June 2026
Independent Blind Screen
JANOSHIK
Actual Content
Label Claim
Purity
Sample:
Sealed lyophilised vial |
Method:
Blind Screen |
Tested:
September 2025 |
Verification Key:
C3YAHLG2JW8B
Quanta Tirzepatide 60mg
is a pharmaceutical-grade
dual agonist peptide
that activates both GLP-1 and GIP receptors. This lyophilized vial from
Quanta Pharma
offers researchers a high-purity compound for advanced studies in glycemic control, weight management, and metabolic health. Independently lab-verified across two laboratories, most recently by Analiza Białek at 99% purity and 61.53mg content. Available for
UK delivery
with fast dispatch.
Tirzepatide 60mg Specifications
Peptide
Tirzepatide
Type
Dual Agonist
Dosage
60mg/vial
Purity
Form
Lyophilized
Half-Life
~5 days
Tirzepatide 60mg
Quanta Pharma
Tirzepatide Research Benefits
Dual receptor action
Glycemic control
Appetite regulation
Weight management
Extended half-life
How Tirzepatide Works
Tirzepatide
is a
dual agonist peptide
that activates two key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action approach enhances insulin secretion while decreasing glucagon levels.
By targeting both GLP-1 and GIP pathways simultaneously, Tirzepatide research has demonstrated significant potential for improved glycemic control and weight management. The extended half-life of approximately 5 days makes it particularly suitable for once-weekly research protocols.
Tirzepatide vs Semaglutide
While
Semaglutide
targets only the GLP-1 receptor,
Tirzepatide
activates both GLP-1 and GIP receptors for a dual-action approach. Research suggests this may offer enhanced effects in metabolic studies, making Tirzepatide a leading compound for laboratory investigation into obesity, type 2 diabetes, and metabolic syndrome.
⚠️ FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE
Safety Classification:
Legal Notice:
This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.
Third-Party Testing 第三方检测
What's in the Box 包装清单
- 1 x lyophilized powder vial (aluminum crimp cap + butyl stopper). Vial label carries batch number and expiry date.
Usage 使用说明
- Reconstitute with sterile or bacteriostatic water per the research protocol. Swirl gently after reconstitution; avoid vigorous shaking. Disinfect the stopper before withdrawing a dose.
Handling & Storage 储存条件
- Unreconstituted: refrigerate at 2-8 C, protect from light. Do not freeze; avoid repeated freeze-thaw cycles. Use within the supplier-stated period after reconstitution.
Applications 应用方向
For research purposes only 免责声明
Information on this entry is compiled from the public sales page (The Ped Shop) and is for research and reference only. Listed products are shown for research use, not sold as drugs or dietary supplements, and are not intended to diagnose, treat, cure or prevent any disease. Actual specification, price and stock are subject to the supplier page.